Secondary Logo

Institutional members access full text with Ovid®

Edaravone prevents memory impairment in an animal model of post-traumatic distress

Alzoubi, Karem H.a; Shatnawi, Alaab; Al-Qudah, Mohammad A.c; Alfaqih, Mahmoud A.b

doi: 10.1097/FBP.0000000000000479

Post-traumatic stress disorder (PTSD) is a mental health problem that develops in a proportion of individuals after experiencing a potential life-threatening traumatic stress event. Edaravone is a free radical scavenger, with a neuroprotective effect against cognitive impairment in several animal models. In the present study, the protective effect of edaravone on PTSD-induced memory impairment was investigated. Single prolonged stress was used as an animal model of PTSD, comprising 2 h of restrain, 20-min forced swimming, 15-min rest, and 1–2-min diethyl ether exposure. Concurrently, edaravone was given at a dose of 6 mg/kg/day, intraperitoneally, for 21 days. The radial arm water maze was used to assess learning and memory. Antioxidant biomarkers were measured in hippocampus tissues. Chronic administration of edaravone prevented impairment of short-term and long-term memory. Edaravone also prevented the stress-induced decrease in the ratio of reduced glutathione/oxidized glutathione and the activities of glutathione peroxidase and catalase enzymes in the hippocampus, as well as increases in the levels of oxidized glutathione and thiobarbituric acid reactive substances. In conclusion, edaravone ameliorated oxidative stress and cognitive impairment associated with a PTSD model, probably by supporting antioxidant mechanism in the hippocampus.

aDepartment of Clinical Pharmacy, Faculty of Pharmacy

bDepartment of Physiology and Biochemistry

cDepartment of Pathology and Microbiology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan

Correspondence to Karem H. Alzoubi, PhD, Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan E-mail:

Received February 1, 2019

Accepted February 16, 2019

Copyright © 2019 YEAR Wolters Kluwer Health, Inc. All rights reserved.